Donaldson Acquires Univercells Technologies, Broadens Life Sciences Reach
29 Junho 2023 - 6:00PM
Business Wire
Donaldson Company, Inc. (NYSE: DCI), a leading worldwide
provider of innovative filtration products and solutions, today
announced the acquisition of Univercells Technologies, a global
producer of innovative biomanufacturing solutions for cell and gene
therapy research, development and commercial manufacturing.
Univercells Technologies’ product offering includes the unique
scale-X™ single-use structured fixed-bed bioreactor for the
intensified production of viruses used in cell and gene therapy,
viral vaccines and other therapeutics. In addition, the Company’s
automated NevoLine™ Upstream platform incorporates
industry-standard filtration to provide integrated up- and
mid-stream processing capabilities in a single unit driving
productivity improvements, reduced operational footprints and
greater consistency of results.
“The acquisition of Univercells Technologies represents an
important next step in Donaldson’s life sciences strategy, as we
continue to expand our product portfolio aimed at providing
customers with a comprehensive, differentiated offering,” said Tod
Carpenter, chairman, president and chief executive officer of
Donaldson. “Univercells Technologies’ engineered systems provide
close adjacencies with our previous life sciences acquisitions as
well as with our growing organic product suite.”
“We are extremely excited to join Donaldson as we grow our
portfolio of best-in-class biomanufacturing platforms and increase
our market penetration and related installed base of equipment,"
said Mathias Garny, chief executive officer of Univercells
Technologies. “Our technology, complemented by Donaldson’s
filtration excellence and existing life sciences capabilities is
part of a larger vision to bring end-to-end solutions to market for
advanced therapies.”
Headquartered in Nivelles, Belgium, Univercells Technologies has
over 100 employees globally. The Company generated approximately
€10 million of revenue in calendar 2022 and was acquired for cash
consideration of €136 million on a cash-free, debt-free basis and
subject to closing adjustments. Univercells Technologies is being
acquired from Gamma Biosciences and Univercells SA and will be a
part of the Donaldson Life Sciences segment. Baker McKenzie acted
as legal advisors to Donaldson.
Statements in this release regarding future events and
expectations, such as forecasts, plans, trends and projections
relating to the Company’s business and financial performance, are
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995 and are identified by
words or phrases such as “will likely result,” “are expected to,”
“will continue,” “will allow,” “estimate,” “project,” “believe,”
“expect,” “anticipate,” “forecast,” “plan” and similar expressions.
These forward-looking statements speak only as of the date such
statements are made and are subject to risks and uncertainties that
could affect the Company’s performance and could cause the
Company’s actual results for future periods to differ materially
from any opinions or statements expressed. These factors include,
but are not limited to, challenges in global operations; impacts of
global economic, industrial and political conditions on product
demand, including the Russia and Ukraine conflict; impacts from
unexpected events, including the COVID-19 pandemic; effects of
unavailable raw materials or material cost inflation; inability to
attract and retain qualified personnel; inability to meet customer
demand; inability to maintain competitive advantages; threats from
disruptive technologies; effects of highly competitive markets with
pricing pressure; exposure to customer concentration in certain
cyclical industries; inability to manage productivity improvements;
results of execution of any acquisition, divestiture and other
strategic transactions; vulnerabilities associated with information
technology systems and security; inability to protect and enforce
intellectual property rights; costs associated with governmental
laws and regulations; impacts of foreign currency fluctuations; and
effects of changes in capital and credit markets. These and other
factors are described in Part I, Item 1A, “Risk Factors” of the
Company’s Annual Report on Form 10-K for the fiscal year ended July
31, 2022. The Company undertakes no obligation to publicly update
or revise any forward-looking statements, whether as a result of
new information, future events or otherwise, unless required by
law.
About Donaldson Company,
Inc.
Founded in 1915, Donaldson (NYSE: DCI) is a global leader in
technology-led filtration products and solutions, serving a broad
range of industries and advanced markets. Our diverse, skilled
employees at over 140 locations on six continents partner with
customers—from small business owners to the world’s biggest OEM
brands—to solve complex filtration challenges. Discover how
Donaldson is Advancing Filtration for a Cleaner World at
www.Donaldson.com.
About Univercells
Technologies
Univercells Technologies is a global provider of innovative
biomanufacturing technologies to achieve cost-effective advanced
therapies and vaccines production from R&D to commercial
scales. The Company offers a comprehensive technology portfolio
leveraging the strengths of process intensification and chaining as
a direct answer to the growing demand of viral vectors and viral
vaccines. Univercells Technologies is committed to helping
customers increase performance with minimized footprint and costs
today, while anticipating the needs of tomorrow.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230629399221/en/
Sarika Dhadwal (952) 887-3753 Sarika.Dhadwal@Donaldson.com
Donaldson (NYSE:DCI)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Donaldson (NYSE:DCI)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024